Clarivate Epidemiology’s coverage of hyperkalemia comprises epidemiological estimates of key patient populations in the major mature pharmaceutical markets (the United States, France, Germany, Italy, Spain, the United Kingdom, and Japan). We report both the incidence and prevalence of hyperkalemia for each country, as well as annualized case counts projected to the national population.
Most patient populations are forecast over a period of 20 years for the major mature pharmaceutical markets.
Clarivate Epidemiology’s hyperkalemia forecast will answer the following questions:
- Of all people with hyperkalemia, how many in each of the major mature pharmaceutical markets have been formally diagnosed?
- Of all people diagnosed with hyperkalemia, how many in each of the major mature pharmaceutical markets are drug-treated?
- How will demographic trends, such as population aging and improving life expectancy, affect the epidemiology of hyperkalemia over the forecast period?
All forecast data are available on the Clarivate Insights Platform in tabular format, with options to download to Excel. All populations are accompanied by a comprehensive description of the methods and data sources used, with hyperlinks to external sources. A summary evidence table generated as part of our systematic review of the epidemiological literature is also provided for full transparency into research and methods.
Clarivate Epidemiology forecasts the following hyperkalemia patient populations:
- Total prevalent cases.
- Total prevalent cases by severity.
- Diagnosed subpopulation(s).
- Treatment subpopulation(s).
- Diagnosed hyperkalemia-related hospitalization events.
- Diagnosed acute hospitalization events.
Note: Coverage may vary by country.
Jackie Liu
Jackie Liu, M.P.H., Ph.D., Manager, Epidemiology. She first joined Clarivate as a Medtech analyst and worked on forecasting the global vascular devices market. She received her Ph.D. in molecular genetics and her M.P.H. in epidemiology from the University of Toronto in Canada.
T.J. Arndt, M.P.H., C.P.H.
Thomas J. Arndt, M.P.H., C.P.H., is a senior epidemiologist at Clarivate. He earned his master’s degree in public health at the University of Florida, where he conducted an internship developing a clinical model for noninvasively screening for nonalcoholic steatohepatitis (NASH). He also holds a B.S. in microbiology and cell science and a B.A. in Spanish, both from the University of Florida. While studying at the University of Florida, Mr. Arndt worked in two physiology-based research labs focusing on maternal and fetal stresses during pregnancy and parturition.